Dossier C, Prim B, Moreau C, et al. - Since B cell depletion using rituximab is effective in preventing relapse in steroid-dependent (SDNS) patients but fails to sustain long-term remission following B cell recovery, possibly due to the development of autoreactive long-lived plasma cells, researchers conducted this monocentric retrospective study to examine the sequential combination of antiCD20 antibody targeting all B cell subsets, and antiCD38 antibody with high plasma cell cytotoxicity in patients with uncontrolled SDNS after failure of one or several attempts at B cell depletion. Fourteen patients (13 males and one female) with SDNS with a median disease duration of 7.8 years received 1,000 mg/1.73 m ² obinutuzumab followed by 1,000 mg/1.73 m ² daratumumab 2 weeks later. In children with difficult-to-treat SDNS, a global antiB cell strategy combining obinutuzumab and daratumumab causes prolonged peripheral B cell depletion and remission.